S&P 500   3,985.43 (+0.36%)
DOW   32,479.67 (+0.75%)
QQQ   308.99 (-0.61%)
AAPL   158.45 (-1.12%)
MSFT   276.28 (-1.53%)
META   202.45 (-1.73%)
GOOGL   102.68 (-2.62%)
AMZN   97.77 (-0.37%)
TSLA   191.76 (+0.71%)
NVDA   266.53 (-0.47%)
NIO   8.94 (-1.43%)
BABA   85.74 (-1.33%)
AMD   96.62 (-1.36%)
T   18.92 (+1.67%)
F   11.54 (+0.26%)
MU   60.20 (-1.57%)
CGC   1.89 (-0.79%)
GE   93.32 (+2.13%)
DIS   95.33 (+1.33%)
AMC   4.41 (-1.34%)
PFE   40.31 (-0.20%)
PYPL   73.71 (-0.23%)
NFLX   326.18 (-0.67%)
S&P 500   3,985.43 (+0.36%)
DOW   32,479.67 (+0.75%)
QQQ   308.99 (-0.61%)
AAPL   158.45 (-1.12%)
MSFT   276.28 (-1.53%)
META   202.45 (-1.73%)
GOOGL   102.68 (-2.62%)
AMZN   97.77 (-0.37%)
TSLA   191.76 (+0.71%)
NVDA   266.53 (-0.47%)
NIO   8.94 (-1.43%)
BABA   85.74 (-1.33%)
AMD   96.62 (-1.36%)
T   18.92 (+1.67%)
F   11.54 (+0.26%)
MU   60.20 (-1.57%)
CGC   1.89 (-0.79%)
GE   93.32 (+2.13%)
DIS   95.33 (+1.33%)
AMC   4.41 (-1.34%)
PFE   40.31 (-0.20%)
PYPL   73.71 (-0.23%)
NFLX   326.18 (-0.67%)
S&P 500   3,985.43 (+0.36%)
DOW   32,479.67 (+0.75%)
QQQ   308.99 (-0.61%)
AAPL   158.45 (-1.12%)
MSFT   276.28 (-1.53%)
META   202.45 (-1.73%)
GOOGL   102.68 (-2.62%)
AMZN   97.77 (-0.37%)
TSLA   191.76 (+0.71%)
NVDA   266.53 (-0.47%)
NIO   8.94 (-1.43%)
BABA   85.74 (-1.33%)
AMD   96.62 (-1.36%)
T   18.92 (+1.67%)
F   11.54 (+0.26%)
MU   60.20 (-1.57%)
CGC   1.89 (-0.79%)
GE   93.32 (+2.13%)
DIS   95.33 (+1.33%)
AMC   4.41 (-1.34%)
PFE   40.31 (-0.20%)
PYPL   73.71 (-0.23%)
NFLX   326.18 (-0.67%)
S&P 500   3,985.43 (+0.36%)
DOW   32,479.67 (+0.75%)
QQQ   308.99 (-0.61%)
AAPL   158.45 (-1.12%)
MSFT   276.28 (-1.53%)
META   202.45 (-1.73%)
GOOGL   102.68 (-2.62%)
AMZN   97.77 (-0.37%)
TSLA   191.76 (+0.71%)
NVDA   266.53 (-0.47%)
NIO   8.94 (-1.43%)
BABA   85.74 (-1.33%)
AMD   96.62 (-1.36%)
T   18.92 (+1.67%)
F   11.54 (+0.26%)
MU   60.20 (-1.57%)
CGC   1.89 (-0.79%)
GE   93.32 (+2.13%)
DIS   95.33 (+1.33%)
AMC   4.41 (-1.34%)
PFE   40.31 (-0.20%)
PYPL   73.71 (-0.23%)
NFLX   326.18 (-0.67%)
NASDAQ:CARA

Cara Therapeutics - CARA Stock Forecast, Price & News

$5.07
+0.15 (+3.05%)
(As of 03/27/2023 01:39 PM ET)
Add
Compare
Today's Range
$4.95
$5.19
50-Day Range
$4.92
$12.27
52-Week Range
$4.85
$13.97
Volume
236,458 shs
Average Volume
600,619 shs
Market Capitalization
$273.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00

Cara Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
232.7% Upside
$17.00 Price Target
Short Interest
Healthy
12.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.39
Upright™ Environmental Score
News Sentiment
0.85mentions of Cara Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$73,938 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.64) to ($0.51) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.72 out of 5 stars

Medical Sector

141st out of 995 stocks

Pharmaceutical Preparations Industry

56th out of 482 stocks


CARA stock logo

About Cara Therapeutics (NASDAQ:CARA) Stock

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

Receive CARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CARA Stock News Headlines

"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
Analyst Ratings for Cara Therapeutics
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
These 2 Stocks Are Plunging After Hours Monday
Cara Therapeutics
Cannabis Stock Movers For December 23, 2022
See More Headlines
Receive CARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CARA Company Calendar

Last Earnings
11/07/2021
Today
3/27/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CARA
Employees
84
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.00
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+232.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-85,470,000.00
Net Margins
-204.16%
Pretax Margin
-204.16%

Debt

Sales & Book Value

Annual Sales
$41.87 million
Book Value
$2.95 per share

Miscellaneous

Free Float
52,217,000
Market Cap
$275.63 million
Optionable
Optionable
Beta
0.99

Key Executives

  • Christopher PosnerChristopher Posner
    President, Chief Executive Officer & Director
  • Ryan D. Maynard
    Chief Financial Officer
  • Frèdèrique Menzaghi
    Chief Scientific Officer, Senior VP-R&D
  • Joana GoncalvesJoana Goncalves
    Chief Medical Officer
  • Scott M. TerrillionScott M. Terrillion
    Secretary & Chief Compliance Officer













CARA Stock - Frequently Asked Questions

Should I buy or sell Cara Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last twelve months. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CARA shares.
View CARA analyst ratings
or view top-rated stocks.

What is Cara Therapeutics' stock price forecast for 2023?

6 Wall Street research analysts have issued 12 month price objectives for Cara Therapeutics' stock. Their CARA share price forecasts range from $6.00 to $25.00. On average, they anticipate the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 232.7% from the stock's current price.
View analysts price targets for CARA
or view top-rated stocks among Wall Street analysts.

How have CARA shares performed in 2023?

Cara Therapeutics' stock was trading at $10.74 on January 1st, 2023. Since then, CARA stock has decreased by 52.4% and is now trading at $5.11.
View the best growth stocks for 2023 here
.

Are investors shorting Cara Therapeutics?

Cara Therapeutics saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 5,140,000 shares, a drop of 6.4% from the February 28th total of 5,490,000 shares. Based on an average trading volume of 588,000 shares, the days-to-cover ratio is presently 8.7 days. Currently, 12.2% of the shares of the company are short sold.
View Cara Therapeutics' Short Interest
.

When is Cara Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our CARA earnings forecast
.

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics, Inc. (NASDAQ:CARA) posted its quarterly earnings data on Sunday, November, 7th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.34. The biopharmaceutical company earned $20.27 million during the quarter, compared to the consensus estimate of $15.74 million. Cara Therapeutics had a negative net margin of 204.16% and a negative trailing twelve-month return on equity of 45.46%. During the same quarter last year, the company posted ($0.35) EPS.

What other stocks do shareholders of Cara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), Novavax (NVAX), INSYS Therapeutics (INSY), Fate Therapeutics (FATE) and Incyte (INCY).

What is Cara Therapeutics' stock symbol?

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

Who are Cara Therapeutics' major shareholders?

Cara Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (1.89%), Geode Capital Management LLC (1.60%), Pinnacle Associates Ltd. (1.32%), Pinnacle Associates Ltd. (1.28%), Bank of America Corp DE (1.25%) and Morgan Stanley (0.92%). Insiders that own company stock include Christopher Posner, Derek T Chalmers, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Martin Vogelbaum, Scott Terrillion and Thomas Charles Reilly.
View institutional ownership trends
.

How do I buy shares of Cara Therapeutics?

Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cara Therapeutics' stock price today?

One share of CARA stock can currently be purchased for approximately $5.11.

How much money does Cara Therapeutics make?

Cara Therapeutics (NASDAQ:CARA) has a market capitalization of $275.63 million and generates $41.87 million in revenue each year. The biopharmaceutical company earns $-85,470,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis.

How can I contact Cara Therapeutics?

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The official website for the company is www.caratherapeutics.com. The biopharmaceutical company can be reached via phone at (203) 406-3700, via email at janhavi.mohite@sternir.com, or via fax at 203-567-1510.

This page (NASDAQ:CARA) was last updated on 3/27/2023 by MarketBeat.com Staff